4 Healthcare Stock Stories For Midweek Investment Wellness

GlaxoSmithKline (NYSE:GSK): Closing price $50.60

The firm recently reached an agreement with Renaissance Acquisition Holdings, granting it rights in the United States to make and commercialize nine Glaxo products that will be marketed by Prestium Pharma, a subsidiary of Renaissance. Financial details of the deal were not divulged. Products covered under the terms include six dermatology products: Evoclin foam, Extina foam, Luxiq foam, Olux foam, Olux-E foam, and Vusion ointment. Three anti-viral products are Zovirax capsules, Zovirax tablets, and Zovirax suspension.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GSK

Eli Lilly and Company (NYSE:LLY): Closing price $51.82

Lilly recently presented some disappointing results on its cancer drug, Alimta (pemetrexed), at the annual meeting of the American Society of Clinical Oncology. The firm said that Alimta did not attain the primary endpoint in the randomized, open-label phase III superiority study PRONOUNCE. The evaluation was conducted in patients suffering from advanced nonsquamous non-small cell lung cancer, and compared Alimta plus carboplatin to a triplet regimen comprised of Taxol (paclitaxel), carboplatin and Avastin (bevacizumab). The Alimta regimen did not exhibit superiority in improving progression-free survival without grade four adverse events (G4PFS). As far as secondary endpoints — including progression-free survival, overall survival, overall response rate, and disease control rate — were concerned, Eli Lilly indicated that there was no major difference between the treatment arms.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LLY

Johnson & Johnson (NYSE:JNJ): Closing price $83.73

India’s number-one publicly traded biotec firm, Biocon Ltd., is in discussions with American drugmakers to co-develop and sell a psoriasis treatment that could compete against Johnson & Johnson’s Stelara. Managing Director Kiran Mazumdar-Shaw said in an interview that she is searching out a partner to assist with expertise and funding for the tests required for approval in the United States. Biocon intends to file for permission in the year ending in March to sell in the United States, and wants to begin marketing Alzumab here two to three years later. Alzumab would provide a novel therapy for a plaque-causing form of the immune disorder that would rival best-selling products from Johnson & Johnson, AbbVie Inc. and Pfizer.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

JNJ

Vivus (NASDAQ:VVUS): Closing price $14.17

The investment advisory firm First Manhattan Co., which currently holds 9.9 percent of Vivus’ outstanding stock, is requesting shareholders to approve its slate of board nominees, thus continuing its drive for new leadership at the company. Vivus had expanded its board from seven to nine members in May. In a letter sent to Vivus shareholders on Tuesday, First Manhattan said that it still thinks Vivus’ stock is undervalued and that the company will never attain full value under its current board.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

VVUS

Don’t Miss: For Johnson & Johnson: Recalls Keep Piling Up.